LGVN

Longeveron Inc. Class A Common Stock (LGVN) | Rumor.io

Longeveron

LGVN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,749

Bullish sentiment (50-day avg)63%

Price to earnings ratio2.95

Market capitalization8.4M

Earnings per share-9.39

Dividend yield (TTM)—

Revenue (annual)1.2M

Net income (annual)-22.7M

Social

What share of all stock conversation is about LGVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 17

Longeveron Inc. ($LGVN) shares have plummeted nearly 60% after a mid-stage trial for infant heart condition failed to meet its primary endpoint.
The company's ELPIS II Phase 2b trial for laromestrocel showed a negative outcome, but a previous trial had shown promise in treating age-related clinical frailty.
Longeveron plans to review its options, including a potential FDA meeting, cost cuts, and a strategic review, as cash runs into Q4 2026.

Generated by AI

Sentiment

Of the messages about LGVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +85	36.96% -47.79	75.29% +3.37
Bearish	—	0% -85	63.04% +47.79	24.71% -3.37

Bullish· Mar 17

$LGVN is showing a potential bull flag formation with small resistance on level 2 and increasing volume, suggesting a potential price increase to $2.00.
Longeveron Inc. has a strong cash position of $9M+ and a low market cap of $19-21M, making it a potentially undervalued stock with high growth potential.
The company has a high ceiling with 5 FDA designations and RMAT status for Alzheimer's, and smart money is accumulating shares in the $0.96 zone before the upcoming earnings call.

Bearish· Sep 17

The company's ELPIS II Phase 2b trial of laromestrocel failed to meet its primary endpoint, with the treatment not significantly improving right ventricular end diastolic volume fraction (RVEF) at 12 months.
Longeveron's shares have plummeted nearly 60% after the trial failure, and the company is undertaking a strategic review to maximize shareholder value, citing a cash runway that will only last through the end of 2026.
The trial failure and subsequent stock drop have led some analysts to predict a potential delisting, with others warning that the company may need to secure additional funding through an offering, which could be risky if it takes too long.

Generated by AI

Topics

Of the messages about LGVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	96.72%	41.41%
Technical Analysis	—	—	1.64%	20.91%
Earnings	—	—	0%	1.04%
Controversies	—	—	1.64%	0.21%
Analysts	—	—	0%	19.36%
Macro	—	—	0%	17.08%

Earnings· Mar 11

Longeveron Inc. (LGVN) reported Q4 2021 GAAP EPS of -$0.20, beating estimates by $0.05.
The company's revenue for Q4 2021 was $209,000, missing estimates by $51,000.
LGVN's CEO discussed the company's Q4 2021 results on an earnings call, citing a delay in key data readout.

Announcements· Mar 13

Longeveron Inc. (LGVN) announced a private placement of up to $30M, providing the company with fresh capital to advance its pipeline and extend its runway.
The private placement will be used to fund the company's pivotal Phase 2b ELPIS II trial.
LGVN stock surged by 74.66% to $0.8100 after the announcement, with trading volume reaching 222M shares.

Technical Analysis· Mar 10

$LGVN is forming a potential pennant at $1.04, with momentum building to break out back to the $1.09-$1.10 range.
$LGVN is in an uptrend, with buyers defending pullbacks and the trend still intact, potentially due for another run if this strength holds.
$LGVN is showing a potential bull flag into new highs, with a clear setup on the chart for a potential breakout, but a break below $1.04 would be a sign of weakness.

Generated by AI

Community

Of the messages about LGVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	61.78%	36.65%
Newcomers	—	100%	38.22%	63.35%

Regulars· Sep 17

Longeveron's Phase 2b trial for laromestrocel in infants with hypoplastic left heart syndrome (HLHS) failed to meet its primary efficacy endpoint, showing no significant difference in right ventricular ejection fraction at Month 12.
The company's shares plummeted 56% after the trial results, and it is now undertaking a strategic review, including cost cutting and exploring "all options" due to its limited cash reserves.
Longeveron has only $10.1 million in cash available to fund operations through the end of the year, and with just 2 hedge funds holding the stock, its market value has been severely impacted.

Newcomers· Sep 17

Longeveron ($LGVN) explores strategic options after stem cell therapy fails mid-stage trial for infant heart condition, with shares plummeting nearly 60%.
The company's laromestrocel treatment showed a 31% numerical reduction in major adverse cardiac events, although the results were not statistically significant, and the treatment group recorded zero deaths during the 12-month period.
Institutional investors, who invested at an effective entry price of approximately $5.20 per share, saw meaningful value in Longeveron and Laromestrocel, and the FDA had already indicated that RVEF was not an appropriate endpoint to establish effectiveness, pointing instead to clinical outcomes such as mortality, transplant-free survival, heart transplantation, and MACE.

Generated by AI

Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct to Stage 2 palliative heart surgery. The primary endpoint measured change in right ventricular ejection fraction, an indicator of pumping […]

7d agoYahoo Finance

Longeveron stock plunges 50% after trial misses primary endpoint

12d agoInvesting.com

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

13d agoYahoo Finance

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026 in New York City. Details for the Company’s presentation: Date:Monday, September 14, 2026 Time:1:00 – 1:30 p.m. ET The webcast for this

26d agoYahoo Finance

Longeveron Announces 1-for-10 Reverse Stock Split

1mo agoBarchart.com

Longeveron Appoints New Chief Financial Officer Jhaveri

Detailed price information for Longeveron Inc (LGVN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about LGVN also mention

#	Name	Attention
1	iSpecimen Inc.ISPC	0%0
2	Biofrontera Inc.BFRI	0%0
3	PTPI - Petros Pharmaceuticals, Inc.	——
4	Pasithea Therapeutics Corp.KTTA	0%0
5	Society Pass IncorporatedSOPA	0%0
6	Context Therapeutics Inc.CNTX	0%0
7	GRCL - Gracell Biotechnologies Inc.	——
8	Immix Biopharma, Inc.IMMX	0.03%+0.03
9	Better Therapeutics, Inc.BTTX	0%new
10	BeyondSpring Inc.BYSI	0%0

Longeveron Inc. Class A Common Stock

Healthcare
Biotechnology

Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions. Its current programs center on Lomecel-B, a lead investigational therapy being studied across several clinical indications, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron’s work spans cell therapy research, clinical development, and translational medicine, placing it within the broader biotechnology sector. Headquartered in Miami, Florida, Longeveron serves as a specialized player in the market for advanced biological treatments aimed at unmet medical needs.

Website

Location

Life Science & Technology Park

Miami, FL, 33136

United States

Social

What share of all stock conversation is about LGVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 17

Longeveron Inc. ($LGVN) shares have plummeted nearly 60% after a mid-stage trial for infant heart condition failed to meet its primary endpoint.
The company's ELPIS II Phase 2b trial for laromestrocel showed a negative outcome, but a previous trial had shown promise in treating age-related clinical frailty.
Longeveron plans to review its options, including a potential FDA meeting, cost cuts, and a strategic review, as cash runs into Q4 2026.

Generated by AI

Sentiment

Of the messages about LGVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +85	36.96% -47.79	75.29% +3.37
Bearish	—	0% -85	63.04% +47.79	24.71% -3.37

Bullish· Mar 17

$LGVN is showing a potential bull flag formation with small resistance on level 2 and increasing volume, suggesting a potential price increase to $2.00.
Longeveron Inc. has a strong cash position of $9M+ and a low market cap of $19-21M, making it a potentially undervalued stock with high growth potential.
The company has a high ceiling with 5 FDA designations and RMAT status for Alzheimer's, and smart money is accumulating shares in the $0.96 zone before the upcoming earnings call.

Bearish· Sep 17

The company's ELPIS II Phase 2b trial of laromestrocel failed to meet its primary endpoint, with the treatment not significantly improving right ventricular end diastolic volume fraction (RVEF) at 12 months.
Longeveron's shares have plummeted nearly 60% after the trial failure, and the company is undertaking a strategic review to maximize shareholder value, citing a cash runway that will only last through the end of 2026.
The trial failure and subsequent stock drop have led some analysts to predict a potential delisting, with others warning that the company may need to secure additional funding through an offering, which could be risky if it takes too long.

Generated by AI

Topics

Of the messages about LGVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	96.72%	41.41%
Technical Analysis	—	—	1.64%	20.91%
Earnings	—	—	0%	1.04%
Controversies	—	—	1.64%	0.21%
Analysts	—	—	0%	19.36%
Macro	—	—	0%	17.08%

Earnings· Mar 11

Longeveron Inc. (LGVN) reported Q4 2021 GAAP EPS of -$0.20, beating estimates by $0.05.
The company's revenue for Q4 2021 was $209,000, missing estimates by $51,000.
LGVN's CEO discussed the company's Q4 2021 results on an earnings call, citing a delay in key data readout.

Announcements· Mar 13

Longeveron Inc. (LGVN) announced a private placement of up to $30M, providing the company with fresh capital to advance its pipeline and extend its runway.
The private placement will be used to fund the company's pivotal Phase 2b ELPIS II trial.
LGVN stock surged by 74.66% to $0.8100 after the announcement, with trading volume reaching 222M shares.

Technical Analysis· Mar 10

$LGVN is forming a potential pennant at $1.04, with momentum building to break out back to the $1.09-$1.10 range.
$LGVN is in an uptrend, with buyers defending pullbacks and the trend still intact, potentially due for another run if this strength holds.
$LGVN is showing a potential bull flag into new highs, with a clear setup on the chart for a potential breakout, but a break below $1.04 would be a sign of weakness.

Generated by AI

Community

Of the messages about LGVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	61.78%	36.65%
Newcomers	—	100%	38.22%	63.35%

Regulars· Sep 17

Longeveron's Phase 2b trial for laromestrocel in infants with hypoplastic left heart syndrome (HLHS) failed to meet its primary efficacy endpoint, showing no significant difference in right ventricular ejection fraction at Month 12.
The company's shares plummeted 56% after the trial results, and it is now undertaking a strategic review, including cost cutting and exploring "all options" due to its limited cash reserves.
Longeveron has only $10.1 million in cash available to fund operations through the end of the year, and with just 2 hedge funds holding the stock, its market value has been severely impacted.

Newcomers· Sep 17

Longeveron ($LGVN) explores strategic options after stem cell therapy fails mid-stage trial for infant heart condition, with shares plummeting nearly 60%.
The company's laromestrocel treatment showed a 31% numerical reduction in major adverse cardiac events, although the results were not statistically significant, and the treatment group recorded zero deaths during the 12-month period.
Institutional investors, who invested at an effective entry price of approximately $5.20 per share, saw meaningful value in Longeveron and Laromestrocel, and the FDA had already indicated that RVEF was not an appropriate endpoint to establish effectiveness, pointing instead to clinical outcomes such as mortality, transplant-free survival, heart transplantation, and MACE.

Generated by AI

Longeveron

Social

Sep 17

Bullish· Mar 17

Bearish· Sep 17

Earnings· Mar 11

Announcements· Mar 13

Technical Analysis· Mar 10

Regulars· Sep 17

Newcomers· Sep 17

Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?

Longeveron stock plunges 50% after trial misses primary endpoint

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Longeveron Announces 1-for-10 Reverse Stock Split

Longeveron Appoints New Chief Financial Officer Jhaveri

Also Discussed

Longeveron Inc. Class A Common Stock

Company Information

Location

Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?

Longeveron stock plunges 50% after trial misses primary endpoint

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Longeveron Announces 1-for-10 Reverse Stock Split

Longeveron Appoints New Chief Financial Officer Jhaveri

Also Discussed

Social

Sep 17

Bullish· Mar 17

Bearish· Sep 17

Earnings· Mar 11

Announcements· Mar 13

Technical Analysis· Mar 10

Regulars· Sep 17

Newcomers· Sep 17